SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
DexCom's Q2 earnings report was disastrous, revealing internal sales channel issues and competitive pressures, leading to a Hold rating and lowered price targets. The company's reliance on channel ...
Despite rival Abbott’s recent U.S. regulatory approval for integration of its Libre 2 and Libre 3 continuous glucose monitors, or CGM, with insulin pumps, we don’t anticipate changing our fair value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback